|Table of Contents|

The impact of tace treatment on postoperative survival and hazard factor analysis of hepatocellular carcinoma patients with portal vein tumor thrombus

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 09
Page:
1658-1663
Research Field:
Publishing date:

Info

Title:
The impact of tace treatment on postoperative survival and hazard factor analysis of hepatocellular carcinoma patients with portal vein tumor thrombus
Author(s):
ZHOU Wenkao1; WANG Mingshan1; TANG Huimin1; ZHAO Fangli1; CHEN Lei1; WANG Yue2; KONG Dequan1
1.Xiang'an Hospital Affiliated to Xiamen University,Fujian Xiamen 361000,China;2.Cancer Hospital Affiliated to China Medical University（Liaoning Provincial Cancer Hospital）,Liaoning Shenyang 110000,China.
Keywords:
TACE; HCC with PVTT; liver resection; nomogram; prognosis
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2024.09.015
Abstract:
Objective:To investigate the postoperative prognosis of patients with PVTT undergoing TACE treatment and establish a relevant clinical predictive model.Methods:204 PVTT patients who underwent R0 resection were included.Based on whether they underwent TACE treatment,they were divided into non-TACE group (n=114) and TACE group (n=90).Cox regression analysis was conducted on OS and RFS data of the 204 patients to obtain independent factors for constructing nomograms.The performance and discriminative ability of the predictive model were assessed using the C-index,calibration curves,and other methods.Results:Among the 204 PVTT patients who underwent R0 resection and had no recurrence within one month,the TACE group showed significantly better OS and RFS than the non-TACE group (P=0.017,P=0.000).Cox regression revealed risk factors affecting OS included Post TBil,Transfusion,Size,and TACE treatment,while factors affecting RFS included Post TBil,Transfusion,Size,TACE,and Post AFP.Nomograms associated with TACE were constructed using these risk factors.The C-index for OS and RFS of this model were 0.73 and 0.75,respectively.Calibration curves indicated good consistency between the predicted and observed outcomes.Conclusion:TACE treatment significantly improves OS and RFS in PVTT patients.The nomogram model developed in this study can predict individual survival and recurrence status in PVTT patients.

References:

［1]VOGEL A,MEYER T,SAPISOCHIN G,et al.Hepatocellular carcinoma［J］.Lancet,2022,400(10360):1345-1362.
［2]GANESAN P,KULIK LM.Hepatocellular carcinoma:New developments［J］.Clin Liver Dis,2023,27(1):85-102.
［3]曹洪祥,黄平.肝细胞癌合并门静脉癌栓的治疗现状［J］.肝胆胰外科杂志,2023,35(04):252-256. CAO HX，HUANG P.Current status of treatment of hepatocellular carcinoma combined with portal vein thrombosis［J］.Journal of Hepatopancreatobiliary Surgery,2023,35(04):252-256.
［4]DING X,SUN W,LI W,et al.Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus:A prospective randomized study［J］.Cancer,2021,127(20):3782-3793.
［5]YANG SB, ZHANG JH,FU YF,et al.TACE with portal vein radioactive seeds for HCC with portal vein tumor thrombus:a meta-analysis［J］.Minim Invasive Ther Allied Technol,2022,31(6):856-864.
［6]YUAN Y,HE W,YANG Z,et al.TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus:a propensity score matching study［J］.Int J Surg,2023,109(5):1222-1230.
［7]GUO L,WEI X,FENG S,et al.Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus:a randomized controlled trial［J］.Hepatol Int,2022,16(6):1368-1378.
［8]LIN H,LUO B,PENG F,et al.The efficacy of transarterial chemoembolization in downstaging unresectable hepatocellular carcinoma to curative therapy:a predicted regression model［J］.Invest New Drugs,2022,40(5):1146-1152.
［9]KHAN AR,WEI X,XU X.Portal vein tumor thrombosis and hepatocellular carcinoma - the changing tides［J］.J Hepatocell Carcinoma,2021,8:1089-1115.
［10]SHUQUN C,MENGCHAO W,HAN C,et al.Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein［J］.Hepatogastroenterology,2007,54(74):499-502.
［11]LUO F,LI M,DING J,et al.The progress in the treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］.Front Oncol,2021,11:635731.
［12]WANG JC,XIA AL,XU Y,et al.Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis［J］.J Cell Physiol,2019,234(2):1062-1070.
［13］代柏树，杨振宇，杜锡林，等.肝细胞癌合并门静脉癌栓的治疗进展［J］.现代肿瘤医学,2018,26（10）:1619-1623. DAI BS,YANG ZY,DU XL,et al.Recent advances on the treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］.Modern Oncology,2018,26（10）:1619-1623.
［14]QIU G,XIE K,JIN Z,et al.The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus［J］.Biosci Trends,2021,15(3):148-154.
［15]DENG ZJ,LI L,TENG YX,et al.Treatments of hepatocellular carcinoma with portal vein tumor thrombus:Current status and controversy［J］.J Clin Transl Hepatol,2022,10(1):147-158.
［16]LI Z,ZHAO M,QI X,et al.Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma［J］.J Cell Mol Med,2023,27(15):2103-2111.
［17]ZHOU XH,LI JR,ZHENG TH,et al.Portal vein tumor thrombosis in hepatocellular carcinoma:molecular mechanism and therapy［J］.Clin Exp Metastasis,2023,40(1):5-32.
［18]FINN RS,IKEDA M,ZHU AX,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.J Clin Oncol,2020,38(26):2960-2970.
［19]FINN RS,QIN S,IKEDA M,et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］.N Engl J Med,2020,382(20):1894-1905.
［20]YUAN J,YIN X,TANG B,et al.Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus:A propensity score matching study［J］.Biomed Res Int,2019,2019:2141859.
［21]LI L,CHENG N,HUANG X,et al.Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type Ⅲ or Ⅳ portal vein tumor thrombosis［J］.World J Surg Oncol,2022,20(1):30.
［22]XIA WL,ZHAO XH,GUO Y,et al.Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma:A multicenter retrospective study［J］.Front Oncol,2022,12:961394.
［23]SHUANGGANG C,SHEN L,QIU Z,et al.Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma:A propensity score matching analysis［J].J Cancer Res Ther,2020,16(2):250-257.
［24]YANG J,KIM JM,RHU J,et al.Surgical resection is preferred in selected solitary hepatocellular carcinoma with portal vein tumor thrombosis［J］.Dig Surg,2022,39(1):42-50.
［25]JEARTH V,PATIL PS,MEHTA S,et al.A study of the clinical profile,predictors,prognostic features,and survival of patients with hepatocellular carcinoma having macroscopic portal vein tumor thrombosis［J］.Indian J Gastroenterol,2022,41(6):533-543.
［26]XU F,ZHANG L,HE W,et al.The diagnostic value of serum PIVKA-II alone or in combination with AFP in chinese hepatocellular carcinoma patients［J］.Dis Markers,2021,2021:8868370.
［27]XU F,ZHANG L,XU Y,et al.Hypermethylation of SCAND3 and Myo1g gene are potential diagnostic biomarkers for hepatocellular carcinoma［J］.Cancers (Basel),2020,12(8):23-32.
［28]ZHANG XP,GAO YZ,CHEN ZH,et al.In-hospital mortality after surgical resection in hepatocellular carcinoma patients with portal vein tumor thrombus［J］.J Cancer,2019,10(1):72-80.
［29]FU YP,YI Y,HUANG JL,et al.Prognostic nomograms stratify survival of patients with hepatocellular carcinoma without portal vein tumor thrombosis after curative resection［J］.Oncologist,2017,22(5):561-569.

Memo

Memo:
-
Last Update: 2024-03-29